True but there are some important hangups. The relationship between Artepharm USA and Artepharm Global (China) needs to be clarified. If all the work is revenue is going to be done from the Chinese company and pretty much kept from the investors eye it raises serious concerns about ARGC retaining revenues they can report on SEC fillings. We won't get serious investors if they play this like a shell company.
-Chris In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten. - Peter Lynch
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.